本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
佐治亞州阿爾法雷塔2025年12月19日 /美通社/ -- 領先的材料科學公司 Arclin 宣佈，已達成協議收購 Willamette Valley Company（簡稱「WVCO」）。WVCO 是一家製造商及分銷商，為木材產品、鐵路、混凝土修復、運輸、基建及消費品領域提供各類定制產品及服務。 Arclin 行政總裁 Bradley Bolduc 表示：「我們熱烈歡迎 Willamette Valley Company 加入我們的機構。」Bolduc 續稱：「他們的創新技術和產品組合與我們的業務完美互補，為我們的客戶創造了雙贏局面。憑藉雙方在木材產品領域對品質的共同承諾，是次收購使我們能夠提供更高的價值，並擴大我們服務領域的發展機會。」 收購 WVCO 是 Arclin 將其材料科學能力擴展至工程修復系統、特種黏合劑及基建解決方案的關鍵一步，而在這些領域中，關鍵性能聚合物和配方對客戶的成果至關重要。此次收購將為 Arclin 現有的 1,200 人團隊增添八間生產設施及約 500 名新成員。 「這項收購代表著極具策略性的一步，具有明顯的營運效益。」Arclin 總裁 Mark Glaspey 表示，「透過結合雙方的能力，我們將為客戶提供更廣泛的解決方案組合，同時擴大地域覆蓋範圍，解鎖新的增長機遇。」 「將 Willamette Valley Company 出售予 Arclin 的決定，代表著我們業務發展的自然進程。」WVCO 總裁兼行政總裁 John Murray 表示，「Arclin 世界級的營運框架將加速我們的產品創新並推動可持續增長。結合 Arclin 和 WVCO 深厚的技術專長、廣博的知識庫以及快速調配資源的能力，將對推動我們的增長策略發揮關鍵作用。加入 Arclin 對我們的團隊來說是一個令人興奮的機會，我們渴望推動業務向前發展。」 關於 Arclin Arclin 是一家領先的材料科學公司，生產聚合物技術、工程產品及專用材料，服務於建築、農業、交通基建、氣候與防火保護、製藥、營養、電子、設計及其他行業。Arclin 總部位於佐治亞州阿爾法雷塔，在美國、加拿大和英國設有辦事處及生產設施，為全球客戶生產產品。如欲查看更多資料，請瀏覽 www.arclin.com。 關於 Willamette Valley Company Willamette Valley Company 成立於 1952 年，是一家專門從事各類化學及應用系統的工程解決方案供應商。WVCO 是一家跨國公司，在全球製造及分銷各類定制產品及服務。雖然他們植根於木材產品行業，但其專業知識和解決方案涵蓋創新的鐵路枕木修復方案、混凝土修復系統、修補劑、填充劑、黏合劑、機械人技術、工程等，遍及數十個行業。如欲了解更多資訊，請瀏覽 https://wilvaco.com The Willamette Valley Company (「WVCO」)
NEW YORK, Dec. 19, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + HawkEye 360 Acquires ISA with $150 Million in Financing Ashley Mastronardi delivers the pre-market update on December 19th Markets look to build off Thursday's gains after the BLS reported cooler-than-expected inflation growth in November with a headline figure of 2.7% HawkEye 360 announces the strategic acquisition of ISA and fresh raise of $150 million in financing. The Shark Beauty Women's Champions Classic rings the Opening Bell ahead of Saturday's doubleheader from the Barclays Center in Brooklyn. UConn Head Coach Geno Auriemma will be on the bell podium for the celebration. Orla Mining (NYSE American: ORLA, NYSE Texas: OLA) will ring the Closing Bell to celebrate its fifth listing anniversary Opening BellKey makers of the Shark Beauty Women's Champions Classic ring the Opening Bell ahead of Saturday's event Closing BellOrla Mining (NYSE American: ORLA) (NYSE Texas: OLA) celebrates its fifth anniversary of listing. Click here to download the NYSE TV App
CARLSBAD, Calif., Dec. 19, 2025 /PRNewswire/ -- With the CDC's Advisory Committee on Immunization Practices (ACIP) recommending post-vaccination antibody testing for hepatitis B, laboratories are facing new demands to assess immunity more effectively. Pictor, a leader in targeted proteomics, today highlighted its ViraScreen-Core™ multiplex antibody assay, an established test already in use by CLIA-certified laboratories, as a ready solution to support this evolving public health guidance. Built for both serum and saliva, the assay offers unmatched flexibility for labs adapting to these changes while addressing broader infectious disease screening needs. Hepatitis B remains a major global health challenge, yet immunity testing has historically been constrained by cost, operational complexity, and single-analyte approaches. Pictor's ViraScreen-Core™ assay enables simultaneous detection of antibodies to hepatitis B, HIV-1, HIV-2, and hepatitis C from a single sample, reducing turnaround time, conserving patient samples, and supporting evidence-based clinical decision-making. "Antibody testing gives laboratories flexibility as public health guidance evolves," said Dr Jamie Platt, CEO of Pictor. "By offering a multiplex assay that works with both serum and saliva, we aim to help labs move toward evidence-based immunity assessment without adding operational complexity." Pictor has completed paired serum and saliva studies demonstrating high concordance, supporting saliva as a reliable testing matrix. This capability may help reduce barriers to testing, particularly in pediatric, community health, and decentralized care settings where blood draws can be challenging. "Pictor's ViraScreen-Core™ assay represents a valuable addition to our clinical laboratory," said Dr Andrew Brown, Chief Commercial Officer at Sirona Dx. "Compatibility with saliva samples expands the environments in which testing can be conducted while the multiplex format supports streamlined, efficient workflows for infectious disease screening." Pictor is actively raising capital to support continued commercialization, assay menu expansion, and U.S. deployment of its targeted proteomics platform, building on early laboratory adoption of its technology. For more information about Pictor's ViraScreen-Core™ assay, visit www.pictordx.com About Pictor Pictor is a leader in flexible, targeted proteomics, delivering next generation multiplex solutions that empower clinical labs, diagnostic manufacturers, and veterinary providers worldwide. Powered by its patented PictArray™ platform, PictImager™, and AI-powered Pictorial™ software, Pictor delivers deeper insights from a single sample, offering faster, more affordable, and scalable results. From infectious diseases to oncology, Pictor's innovative technology is advancing both human and animal health, enabling breakthroughs in clinical decision-making. Headquartered in San Diego, Pictor Holdings Inc. is committed to driving innovation through solutions designed for unmatched performance, cost efficiency and productivity. Discover how Pictor is shaping the future of proteomics testing at www.pictordx.com. About Sirona Dx Sirona Dx is technical CRO shaping the next generation of diagnostics to accelerate therapeutic development and advance precision medicine initiatives. Built at the intersection of science and technology, Sirona Dx is driven by innovation because enhanced diagnostics lead to better outcomes. For more information, visit www.sironadx.com. Legal Disclaimer / Forward-Looking Statements This press release is not an offer to sell securities or a solicitation of an offer to buy any securities and may not be relied upon in connection with the purchase or sale of any company security. This release may contain forward-looking statements regarding, amongst other things, the company's expansion plans, product development initiatives, financing objectives, strategic partnership outcomes, and market positioning. Such statements are forward-looking statements and there can be no assurance that the results stated or implied by these forward-looking statements will actually be realized or achieved by the company. Forward-looking statements may be based on management assumptions that could prove to be incorrect. The company's predictions may not be realized for a variety of reasons as the company's business is subject to substantial risks and potential events beyond its control that could cause material differences between predicted and actual results. Media Contact:Kelly Krueger415-235-5031Kelly.krueger@audacityhealth.com
以卓越語音清晰度、智慧感測能力與電池續航力，全面升級穿戴式裝置、AR/VR、無人機與物聯網應用 台北2025年12月19日 /美通社/ -- 超低功耗運算、語音與邊緣 AI 感測解決方案的先驅 Upbeat Technology 今日宣布推出全新 UPM01 與 UPM02 高頻寬 MEMS 振動感測器系列。新產品具備 5 Hz 至 12 kHz 的平坦頻率響應，以及最高 68 dB 的訊噪比（SNR），專為新世代聲學、語音介面與智慧感測應用而設計。 Upbeat Tech UPM01 and UPM02 Vi 當搭配 Upbeat 的 UP301 雙核心 RISC-V AI MCU 使用時，該 MEMS 感測產品組合可在高噪音或強烈振動的環境中，提供傳統空氣傳導麥克風或多麥克風陣列難以達成的抗噪訊號品質。Upbeat 將於 CES 2026（1 月 6–9 日） 在 Eureka Park，Venetian Ballroom 的 62201 號攤位現場展示此新推出的感測平台。 UPM01 與 UPM02 感測器系列支援多元且先進的應用，涵蓋 AI 穿戴式裝置、人形機器人、無人機與自動化系統。在設計彈性方面，UPM01 與 UPM02 同時整合類比與數位介面，可輕鬆整合至各式系統架構，樹立產業新標竿。在 AI 智慧型眼鏡、真無線立體聲（TWS）耳機與開放式穿戴立體聲（OWS）耳機中，UPM02 感測器能有效進行語音隔離，精準擷取使用者聲音並抑制環境噪音，實現清晰通話與高度可靠的語音指令辨識，支援全天候、免持操作的 AI 介面。 在無人機與機器人平台應用中，UPM01 振動感測器可偵測極微小的振動訊號，辨識因機械失衡、疲勞或磨損 所產生的異常。此能力可實現預測性維護、螺旋槳健康監測與自動系統診斷，滿足低空經濟對於操作穩定性與設備壽命的關鍵需求。UPM01 已於 2025 年全年進行大規模量產並出貨，並成功應用於實際的智慧眼鏡與 TWS 產品中，展現其成熟穩定的實戰效能。 Parks Associates 資深分析師 Daniel Holcomb 表示：「超低功耗解決方案能滿足消費者對長效電池續航的核心需求，而這正是穿戴式裝置買家最重視的評估指標。Parks Associates 的研究顯示，78% 的穿戴式裝置使用者希望擁有更長的電池續航力。像 Upbeat Technology 的 UPM01 與 UPM02 這類解決方案，突顯了以振動為基礎的感測技術，如何在 AI 穿戴式裝置、機器人與無人機等領域開創新應用，而這些正是傳統音訊技術難以勝任之處。」 UPM01 與 UPM02 共同展現 Upbeat 在 MEMS 感測解決方案上的實力，能從消費性音訊延伸至關鍵任務型自動化系統。UPM02 為 AI 穿戴式裝置提供錄音室等級的語音隔離效果，而 UPM01 則可在需要時，同步擷取說話者聲音與環境環繞音。 J5Create 執行長劉總（SJ Liu） 表示：「我們非常高興將 Upbeat Tech 的 UPM01 骨傳導 MEMS 感測器整合至我們的產品中。其高靈敏度、卓越的訊噪比與寬頻寬特性，即使在最嘈雜的環境中也能清晰收音，為使用者帶來顯著提升的音訊體驗。」 在消費性電子裝置中，此 MEMS + MCU 的整合方案可支援耳機、智慧型眼鏡、AI 穿戴式裝置及超薄錄音配件。當 UPM01/UPM02 整合至耳機或眼鏡鏡框中，即使在會使傳統麥克風效能下降的嘈雜環境裡，UPM01/UPM02 仍能實現清晰通訊、低聲（耳語）輸入與穩定的語音指令操作。此外，結合 UPM01/UPM02 的磁吸式超薄錄音卡也可藉由振動擷取電話通話雙方的聲音，支援逐字稿、翻譯與會議摘要等應用。 除 UPM01 與 UPM02 外，Upbeat 亦將推出 UPM05 超音波 MEMS 感測器，預計於 2026 年第三季開始提供合作夥伴使用。歡迎造訪https://www.upbeattechtw.com/Products/upbeat-mems以取得參考設計、評估套件、影片與產品簡介。 關於 Upbeat Technology Upbeat Technology 總部位於台灣台北，是超低功耗運算、語音與邊緣 AI 感測領域的獲獎先驅，擁有多項微結構與 AI 加速技術專利。其 UP201/UP301 系列 MCU 採用雙核心 RISC-V 處理器，廣泛應用於從感測器到工業系統的各式物聯網裝置；而 UPM01/UPM02 骨傳導 MEMS 麥克風則為穿戴式與語音應用提供卓越音質。Upbeat 的解決方案專為全天候運作的物聯網、無人機與智慧工廠而最佳化，並與全球夥伴攜手打造智慧、永續且高能源效率的連網系統。更多資訊請聯繫：info@Upbeattechtw.com或造訪 Upbeattechtw.com. 媒體聯絡人：Linda Ferguson+1-503-869-5827linda@upbeattechtw.com
A12 藝術空間
D-Link
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
